TY - JOUR
T1 - RAS mutations as predictive biomarkers in clinical management of metastatic colorectal cancer
AU - Waring, Paul
AU - Tie, Jeanne
AU - Maru, Dipen
AU - Karapetis, Christos S.
N1 - Funding Information:
C. S. Kareptis has participated in Celgene, Amgen, and Merck Serono advisory boards. D. Maru has received research funding from Taiho Pharmaceuticals. The remaining authors have no conflicts of interest to disclose. No financial support or compensation was received for publication.
Funding Information:
We acknowledge the medical writing assistance provided by Doreen Valentine, PhD, from ClinicalThinking (Hamilton, NJ), which was funded by Bristol-Myers Squibb .
Publisher Copyright:
© 2016 Elsevier Inc. All rights reserved.
PY - 2016/6/1
Y1 - 2016/6/1
N2 - The use of anti-epidermal growth factor receptor (EGFR) monoclonal antibody therapies in patients with metastatic colorectal cancer is guided by the presence of activating point mutations in codons 12, 13, 59, 61, 117, and 146 of the KRAS and NRAS genes in the primary tumor. Although these mutations have been incorporated into the prescribing information for both cetuximab and panitumumab, highlighted in the National Comprehensive Cancer Network Guidelines, and routinely tested, a number of controversial issues and unanswered questions related to these mutations and their clinical significance remain. In the present review, we explored the contradictory data related to the prognostic value of KRAS mutations, the reported frequent discordance of KRAS mutations, and the reported nonequivalence of some of these mutations. We also considered the issues related to incorporating additional mutations into the already accredited and approved assays and the challenges created by changing an assay's analytical and clinical limits of detection. We also discuss the lack of biologic data supporting the pathogenicity of newly described clinically actionable mutations and explore the uncertainty regarding the clinical significance of low-frequency mutations, highlighting the importance of correcting allele frequencies for tumor purity. We also considered the importance of distinguishing the significance of low-frequency RAS mutations in tumors previously not treated or treated with anti-EGFR therapies and explore new technologies capable of detecting emerging polyclonal RAS mutations that appear to confer drug resistance.
AB - The use of anti-epidermal growth factor receptor (EGFR) monoclonal antibody therapies in patients with metastatic colorectal cancer is guided by the presence of activating point mutations in codons 12, 13, 59, 61, 117, and 146 of the KRAS and NRAS genes in the primary tumor. Although these mutations have been incorporated into the prescribing information for both cetuximab and panitumumab, highlighted in the National Comprehensive Cancer Network Guidelines, and routinely tested, a number of controversial issues and unanswered questions related to these mutations and their clinical significance remain. In the present review, we explored the contradictory data related to the prognostic value of KRAS mutations, the reported frequent discordance of KRAS mutations, and the reported nonequivalence of some of these mutations. We also considered the issues related to incorporating additional mutations into the already accredited and approved assays and the challenges created by changing an assay's analytical and clinical limits of detection. We also discuss the lack of biologic data supporting the pathogenicity of newly described clinically actionable mutations and explore the uncertainty regarding the clinical significance of low-frequency mutations, highlighting the importance of correcting allele frequencies for tumor purity. We also considered the importance of distinguishing the significance of low-frequency RAS mutations in tumors previously not treated or treated with anti-EGFR therapies and explore new technologies capable of detecting emerging polyclonal RAS mutations that appear to confer drug resistance.
KW - Cetuximab
KW - KRAS
KW - NRAS
KW - Panitumumab
KW - mCRC
UR - http://www.scopus.com/inward/record.url?scp=84959549216&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84959549216&partnerID=8YFLogxK
U2 - 10.1016/j.clcc.2015.10.006
DO - 10.1016/j.clcc.2015.10.006
M3 - Review article
C2 - 26952655
AN - SCOPUS:84959549216
SN - 1533-0028
VL - 15
SP - 95
EP - 103
JO - Clinical colorectal cancer
JF - Clinical colorectal cancer
IS - 2
ER -